NCT06221111
Comparison of Rimegepant and Placebo for Pain in IBS
Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study
Mayo Clinic·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Irritable Bowel Syndrome
- Drug/Device/Intervention
- Rimegepant 75 MG [Nurtec]
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Mayo Clinic
- Location
- Rochester, United States of America
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Apr 15, 2024
- End date
- Jun 01, 2025
- Enrollment
- 24 participants
Primary outcome
abdominal pain
Summary
The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain
 scores in participants with non-constipation IBS.
ICD-10 classifications
Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06221111
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06221111 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.